Conference call to take place Friday, May 11, 2018 at 8:30 am Eastern time
ISNES, Belgium, May 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, May 11 at 8:30 a.m. Eastern time to discuss its financial and operating results from the first quarter of 2018, in conjunction with the filing of its quarterly report on Form 10-Q for the first quarter ended March 31, 2018.
Event: VolitionRx Limited First Quarter 2018 Earnings and Business Update Conference Call
Date: Friday, May 11, 2018
Time: 8:30 a.m. Eastern time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Conference ID: 13679703
Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President. The call will provide an update on recent developments and Volition's international activities, including details of new and ongoing clinical trials, important events which have taken place in this quarter, and milestones for 2018 and beyond.
A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volitionrx.com. In addition, a telephone replay of the call will be available until May 25, 2018. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13679703.
Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
Nucleosomics® is a trademark of VolitionRx Limited and its subsidiaries.
For more information about Volition, visit Volition's website https://volitionrx.com/
or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
SOURCE VolitionRx Ltd